Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oruka Therapeutics, Inc. - Common Stock (NQ:ORKA)

16.00 +1.10 (+7.38%)
Streaming Delayed Price Updated: 12:53 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oruka Therapeutics, Inc. - Common Stock

Oruka Therapeutics Announces $180 Million Private Placement
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics to Present at Multiple March Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics to Present at Multiple November Investor Conferences
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces $200 Million Private Placement
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
From Oruka Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.